Egetis Therapeutics ABPDPHF 24 PB Ratio is 9.48 as of Jun. 25, 2026, which is 245% above its 10-year median of 2.75. GuruFocus rates PDPHF with a GF Score™ of 24/100 and a GF Value™ of $0.64 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,233 Biotechnology companies, Egetis Therapeutics AB ranks worse than 84.59% on this metric.
The historical rank and industry rank for Egetis Therapeutics AB's PB Ratio or its related term are showing as below:
PDPHF'
s PB Ratio Range Over the Past 10 Years
Min: 1.13 Med: 2.75 Max: 10.76
Current: 8.36
During the past 13 years, Egetis Therapeutics AB's highest PB Ratio was 10.76. The lowest was 1.13. And the median was 2.75.
PDPHF's PB Ratio is ranked worse than 84.59% of 1233
companies
in the Biotechnology industry
Industry Median: 2.83
vs PDPHF: 8.36
During the past 12 months, Egetis Therapeutics AB's average Book Value Per Share Growth Rate was -47.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -28.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -23.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -12.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Egetis Therapeutics AB was 65.10% per year. The lowest was -51.70% per year. And the median was -14.70% per year.
Back to Basics: PB Ratio
Egetis Therapeutics AB (OTCPK:PDPHF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Egetis Therapeutics AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egetis Therapeutics AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Egetis Therapeutics AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Egetis Therapeutics AB (PDPHF) has a PB Ratio of 9.48 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Egetis Therapeutics AB and its competitors. This is 245% above median its historical median of 2.75. Over the past decade, Egetis Therapeutics AB's PB Ratio has ranged from 1.13 to 10.76. According to the industry distribution chart, Egetis Therapeutics AB ranks #1043 out of 1233 companies in the Biotechnology industry, placing it in the top 84.6%.
Is Egetis Therapeutics AB's PB Ratio too high?
Egetis Therapeutics AB's current PB Ratio of 9.48 is 245% above median its 10-year median of 2.75. Over the past 10 years, this metric has ranged from a low of 1.13 to a high of 10.76. The Biotechnology industry median PB Ratio is 2.83. Egetis Therapeutics AB's value of 9.48 is 235% above this industry median. Based on the distribution chart, Egetis Therapeutics AB ranks #1043 out of 1233 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Egetis Therapeutics AB has a GF Score™ of 24/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Egetis Therapeutics AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Egetis Therapeutics AB ranks #1043 out of 1233 companies for PB Ratio. This places Egetis Therapeutics AB in the lower half of its industry. The industry median PB Ratio is 2.83. Egetis Therapeutics AB's value of 9.48 is 235% above this benchmark. Historically, Egetis Therapeutics AB's own PB Ratio has ranged from 1.13 to 10.76 over the past decade. While the company's 10-year median is 2.75 vs. the industry median of 2.83, Egetis Therapeutics AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.83, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Egetis Therapeutics AB's current PB Ratio of 9.48 is 235% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Egetis Therapeutics AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egetis Therapeutics AB's current PB Ratio is 9.48, which is 245% above median its own 10-year median of 2.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egetis Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, Egetis Therapeutics AB (PDPHF) is currently considered Fairly Valued. The stock's GF Value™ is $0.64, compared to a current price of $0.64 — trading 0.7% below its estimated fair value. The current PB Ratio is 9.48, which is 245% above median its 10-year median of 2.75 and 235% above the Biotechnology industry median of 2.83. Egetis Therapeutics AB's overall GF Score™ is 24/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Egetis Therapeutics AB (PDPHF), the current PB Ratio is 9.48 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egetis Therapeutics AB (PDPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be undervalued.
The current stock price of $0.64 is trading 0.7% below its estimated GF Value™ of $0.64.
GuruFocus considers Egetis Therapeutics AB to be Fairly Valued.
Key valuation signals for PDPHF:
PB Ratio: 9.48 (245% above median its 10-year median of 2.75)
GF Value™: $0.64 vs. price of $0.64 (0.7% below fair value)
Industry Position: 235% above the Biotechnology median (#1043 of 1233)
No single metric tells the full story. See the PDPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
24GF Score
Get the complete analysis for PDPHF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PDPHF has been successfully added to your 
